一种新型的针对癌症的联合免疫疗法，通过靶向 IL-13Rα2 的 DNA 疫苗和免疫毒素在小鼠肿瘤模型中实现。
A novel combination immunotherapy for cancer by IL-13Rα2-targeted DNA vaccine and immunotoxin in murine tumor models.
机构信息
Tumor Vaccines and Biotechnology Branch, Division of Cellular and Gene Therapies, Center for Biologics Evaluation and Research, U.S. Food and Drug Administration, Bethesda, MD 20892, USA.
出版信息
J Immunol. 2011 Nov 15;187(10):4935-46. doi: 10.4049/jimmunol.1102095. Epub 2011 Oct 17.
Abstract
Optimum efficacy of therapeutic cancer vaccines may require combinations that generate effective antitumor immune responses, as well as overcome immune evasion and tolerance mechanisms mediated by progressing tumor. Previous studies showed that IL-13Rα2, a unique tumor-associated Ag, is a promising target for cancer immunotherapy. A targeted cytotoxin composed of IL-13 and mutated Pseudomonas exotoxin induced specific killing of IL-13Rα2(+) tumor cells. When combined with IL-13Rα2 DNA cancer vaccine, surprisingly, it mediated synergistic antitumor effects on tumor growth and metastasis in established murine breast carcinoma and sarcoma tumor models. The mechanism of synergistic activity involved direct killing of tumor cells and cell-mediated immune responses, as well as elimination of myeloid-derived suppressor cells and, consequently, regulatory T cells. These novel results provide a strong rationale for combining immunotoxins with cancer vaccines for the treatment of patients with advanced cancer.
摘要
最佳疗效的治疗性癌症疫苗可能需要联合应用，以产生有效的抗肿瘤免疫反应，同时克服进展性肿瘤介导的免疫逃逸和耐受机制。先前的研究表明，白细胞介素 13 受体α2（IL-13Rα2）是一种独特的肿瘤相关抗原，是癌症免疫治疗的一个很有前途的靶点。由白细胞介素 13 和突变型绿脓杆菌外毒素组成的靶向细胞毒素可诱导特异性杀伤 IL-13Rα2（+）肿瘤细胞。令人惊讶的是，当与 IL-13Rα2 DNA 癌症疫苗联合使用时，它在已建立的小鼠乳腺癌和肉瘤肿瘤模型中对肿瘤生长和转移具有协同的抗肿瘤作用。协同作用的机制涉及肿瘤细胞的直接杀伤和细胞介导的免疫反应，以及髓源抑制细胞和调节性 T 细胞的消除。这些新的结果为将免疫毒素与癌症疫苗联合用于治疗晚期癌症患者提供了强有力的依据。
相似文献
1
A novel combination immunotherapy for cancer by IL-13Rα2-targeted DNA vaccine and immunotoxin in murine tumor models.一种新型的针对癌症的联合免疫疗法，通过靶向 IL-13Rα2 的 DNA 疫苗和免疫毒素在小鼠肿瘤模型中实现。
J Immunol. 2011 Nov 15;187(10):4935-46. doi: 10.4049/jimmunol.1102095. Epub 2011 Oct 17.
2
Interleukin 13 mediates signal transduction through interleukin 13 receptor alpha2 in pancreatic ductal adenocarcinoma: role of IL-13 Pseudomonas exotoxin in pancreatic cancer therapy.白细胞介素 13 通过白细胞介素 13 受体 alpha2 在胰腺导管腺癌中介导信号转导：白细胞介素 13 假单胞菌外毒素在胰腺癌治疗中的作用。
Clin Cancer Res. 2010 Jan 15;16(2):577-86. doi: 10.1158/1078-0432.CCR-09-2015. Epub 2010 Jan 12.
3
Human adrenomedullin up-regulates interleukin-13 receptor alpha2 chain in prostate cancer in vitro and in vivo: a novel approach to sensitize prostate cancer to anticancer therapy.人肾上腺髓质素在体外和体内上调前列腺癌中白细胞介素-13受体α2链：一种使前列腺癌对抗癌治疗敏感的新方法。
Cancer Res. 2008 Nov 15;68(22):9311-7. doi: 10.1158/0008-5472.CAN-08-2810.
4
A Novel Recombinant Modified Vaccinia Ankara Virus expressing Interleukin-13 Receptor α2 Antigen for Potential Cancer Immunotherapy.一种新型表达白细胞介素 13 受体 α2 抗原的改良安卡拉痘苗病毒用于潜在的癌症免疫治疗。
Curr Mol Med. 2024;24(6):758-770. doi: 10.2174/1566524023666230331085007.
5
An immunotoxin targeting the gH glycoprotein of KSHV for selective killing of cells in the lytic phase of infection.一种针对 KSHV 的 gH 糖蛋白的免疫毒素，用于选择性杀伤感染裂解期的细胞。
Antiviral Res. 2011 Jun;90(3):143-50. doi: 10.1016/j.antiviral.2011.03.175. Epub 2011 Mar 31.
6
Mechanisms of immunization against cancer using chimeric antigens.使用嵌合抗原进行癌症免疫的机制。
Mol Ther. 2008 Apr;16(4):773-81. doi: 10.1038/mt.2008.8. Epub 2008 Feb 26.
7
Heterogeneity in interleukin-13 receptor expression and subunit structure in squamous cell carcinoma of head and neck: differential sensitivity to chimeric fusion proteins comprised of interleukin-13 and a mutated form of Pseudomonas exotoxin.头颈部鳞状细胞癌中白细胞介素-13受体表达及亚基结构的异质性：对由白细胞介素-13和铜绿假单胞菌外毒素突变形式组成的嵌合融合蛋白的不同敏感性
Clin Cancer Res. 2002 Jun;8(6):1948-56.
8
New Life for Immunotoxin Cancer Therapy.免疫毒素癌症治疗的新生命。
Clin Cancer Res. 2016 Mar 1;22(5):1055-8. doi: 10.1158/1078-0432.CCR-15-1623. Epub 2015 Oct 13.
9
An immunotoxin with greatly reduced immunogenicity by identification and removal of B cell epitopes.一种通过识别和去除B细胞表位而使免疫原性大大降低的免疫毒素。
Proc Natl Acad Sci U S A. 2008 Aug 12;105(32):11311-6. doi: 10.1073/pnas.0804851105. Epub 2008 Aug 4.
10
IL-13 receptor-directed cancer vaccines and immunotherapy.白细胞介素-13 受体导向的癌症疫苗和免疫疗法。
Immunotherapy. 2012 Apr;4(4):443-51. doi: 10.2217/imt.12.28.
引用本文的文献
1
Exploring the causal relationship between the immune cell-inflammatory factor axis and lung cancer: a Mendelian randomization study.探索免疫细胞-炎症因子轴与肺癌之间的因果关系：一项孟德尔随机化研究
Front Oncol. 2024 Aug 29;14:1345765. doi: 10.3389/fonc.2024.1345765. eCollection 2024.
2
Ovarian cancer ascites proteomic profile reflects metabolic changes during disease progression.卵巢癌腹水蛋白质组学图谱反映疾病进展过程中的代谢变化。
Biochem Biophys Rep. 2024 Jun 13;39:101755. doi: 10.1016/j.bbrep.2024.101755. eCollection 2024 Sep.
3
Targeting Interleukin-13 Receptor α2 and EphA2 in Aggressive Breast Cancer Subtypes with Special References to Chimeric Antigen Receptor T-Cell Therapy.针对侵袭性乳腺癌亚型的白细胞介素-13 受体 α2 和 EphA2 及其嵌合抗原受体 T 细胞治疗的特殊参考。
Int J Mol Sci. 2024 Mar 28;25(7):3780. doi: 10.3390/ijms25073780.
4
Inflammatory cytokines mediating the effect of oral lichen planus on oral cavity cancer risk: a univariable and multivariable mendelian randomization study.介导口腔扁平苔藓对口腔癌风险影响的炎症细胞因子：单变量和多变量孟德尔随机化研究。
BMC Oral Health. 2024 Mar 22;24(1):375. doi: 10.1186/s12903-024-04104-0.
5
Targeting of the Interleukin-13 Receptor (IL-13R)α2 Expressing Prostate Cancer by a Novel Hybrid Lytic Peptide.新型融合裂解肽靶向表达白细胞介素-13 受体 (IL-13R)α2 的前列腺癌。
Biomolecules. 2023 Feb 12;13(2):356. doi: 10.3390/biom13020356.
6
Immunotherapy in soft tissue and bone sarcoma: unraveling the barriers to effectiveness.软组织和骨肉瘤的免疫治疗：揭开疗效的障碍。
Theranostics. 2022 Aug 15;12(14):6106-6129. doi: 10.7150/thno.72800. eCollection 2022.
7
Recent Advances in IL-13Rα2-Directed Cancer Immunotherapy.IL-13Rα2 导向的癌症免疫治疗的最新进展。
Front Immunol. 2022 Apr 8;13:878365. doi: 10.3389/fimmu.2022.878365. eCollection 2022.
8
IL-13Rα2 Regulates the IL-13/IFN-γ Balance during Innate Lymphoid Cell and Dendritic Cell Responses to Pox Viral Vector-Based Vaccination.IL-13Rα2在天然淋巴细胞和树突状细胞对痘病毒载体疫苗接种的反应过程中调节IL-13/IFN-γ平衡。
Vaccines (Basel). 2021 May 1;9(5):440. doi: 10.3390/vaccines9050440.
9
Lymph Node Subcapsular Sinus Microenvironment-On-A-Chip Modeling Shear Flow Relevant to Lymphatic Metastasis and Immune Cell Homing.淋巴结被膜下窦微环境芯片模型：模拟与淋巴转移和免疫细胞归巢相关的剪切流
iScience. 2020 Oct 31;23(11):101751. doi: 10.1016/j.isci.2020.101751. eCollection 2020 Nov 20.
10
Intratumorally delivered formulation, INT230-6, containing potent anticancer agents induces protective T cell immunity and memory.瘤内递送制剂 INT230-6 含有有效的抗癌药物，可诱导保护性 T 细胞免疫和记忆。
Oncoimmunology. 2019 Jul 16;8(10):e1625687. doi: 10.1080/2162402X.2019.1625687. eCollection 2019.
本文引用的文献
1
PROVENGE (Sipuleucel-T) in prostate cancer: the first FDA-approved therapeutic cancer vaccine.普罗文奇（前列腺癌疫苗 sipuleucel-T）：首个获得 FDA 批准的治疗性癌症疫苗。
Clin Cancer Res. 2011 Jun 1;17(11):3520-6. doi: 10.1158/1078-0432.CCR-10-3126. Epub 2011 Apr 6.
2
Interleukin-13 receptor α2 DNA prime boost vaccine induces tumor immunity in murine tumor models.白细胞介素-13 受体 α2 DNA 初免-加强疫苗在鼠肿瘤模型中诱导肿瘤免疫。
J Transl Med. 2010 Nov 10;8:116. doi: 10.1186/1479-5876-8-116.
3
Targeting IL-13Rα2 in human pancreatic ductal adenocarcinoma with combination therapy of IL-13-PE and gemcitabine.用 IL-13-PE 和吉西他滨联合疗法靶向人胰腺导管腺癌的 IL-13Rα2。
Int J Cancer. 2011 Mar 1;128(5):1221-31. doi: 10.1002/ijc.25437.
4
A novel role of interleukin-13 receptor alpha2 in pancreatic cancer invasion and metastasis.白细胞介素-13受体α2在胰腺癌侵袭和转移中的新作用
Cancer Res. 2009 Nov 15;69(22):8678-85. doi: 10.1158/0008-5472.CAN-09-2100. Epub 2009 Nov 3.
5
Myeloid-derived suppressor cells as regulators of the immune system.髓源性抑制细胞作为免疫系统的调节因子。
Nat Rev Immunol. 2009 Mar;9(3):162-74. doi: 10.1038/nri2506.
6
IL-13 cytotoxin has potent antitumor activity and synergizes with paclitaxel in a mouse model of oral squamous cell carcinoma.白细胞介素-13细胞毒素具有强大的抗肿瘤活性，并在口腔鳞状细胞癌小鼠模型中与紫杉醇协同作用。
Int J Cancer. 2009 Mar 15;124(6):1440-8. doi: 10.1002/ijc.24067.
7
Increased circulating myeloid-derived suppressor cells correlate with clinical cancer stage, metastatic tumor burden, and doxorubicin-cyclophosphamide chemotherapy.循环中髓源性抑制细胞增加与临床癌症分期、转移性肿瘤负荷及多柔比星-环磷酰胺化疗相关。
Cancer Immunol Immunother. 2009 Jan;58(1):49-59. doi: 10.1007/s00262-008-0523-4. Epub 2008 Apr 30.
8
DNA vaccines: precision tools for activating effective immunity against cancer.DNA疫苗：激活针对癌症的有效免疫的精准工具。
Nat Rev Cancer. 2008 Feb;8(2):108-20. doi: 10.1038/nrc2326.
9
Enhancing efficacy of therapeutic vaccinations by combination with other modalities.通过与其他方式联合使用来提高治疗性疫苗的疗效。
Vaccine. 2007 Sep 27;25 Suppl 2(Suppl 2):B89-96. doi: 10.1016/j.vaccine.2007.04.091. Epub 2007 Jun 4.
10
Mechanism and therapeutic reversal of immune suppression in cancer.癌症免疫抑制的机制与治疗性逆转
Cancer Res. 2007 Jun 1;67(11):5067-9. doi: 10.1158/0008-5472.CAN-07-0897.
Zotero 插件